Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lowe`s Companies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.27 (market cap $29.60B), while Lowe`s Companies Inc trades at $220.52 (market cap $124.06B). The key difference: Lowe`s Companies Inc is far larger — about 4.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Lowe`s Companies Inc pays a 2.26% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LOW | |
|---|---|---|
Market Cap | $29.60B | $124.06B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $287.39 |
52-Week Low | $205.48 | $201.92 |
Enterprise Value | $27.56B | $165.81B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Lowe's (LOW) trades at $218.84, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company has beaten earnings estimates for the last three quarters, with Q2 2026 results expected on August 19. Revenue declined to $83.67 billion in 2025, but net income margin remained healthy at 7.51%. A $1.25 dividend is scheduled for payment on August 5, 2026.
The outlook is supported by strong analyst consensus, with a $257.06 price target implying 17% upside. Risks include high debt levels and competitive pressures. Earnings growth in the professional segment is a key catalyst, but macroeconomic headwinds could challenge DIY sales momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
